Connor, Clark & Lunn Investment Management (CC&L)’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-153,755
| Closed | -$20.3M | – | 1738 |
|
|
2026
Q1 | $20.3M | Sell |
153,755
-92,534
| -38% | -$12.3M | 0.05% | 313 |
|
|
2025
Q4 | $34.9M | Sell |
246,289
-34,824
| -12% | -$5.05M | 0.09% | 183 |
|
|
2025
Q3 | $39.5M | Buy |
281,113
+32,480
| +13% | +$4.4M | 0.12% | 156 |
|
|
2025
Q2 | $31.3M | Buy |
248,633
+192,768
| +345% | +$22.1M | 0.11% | 165 |
|
|
2025
Q1 | $6.18M | Sell |
55,865
-7,717
| -12% | -$978K | 0.03% | 448 |
|
|
2024
Q4 | $8.68M | Buy |
63,582
+46,396
| +270% | +$5.74M | 0.04% | 357 |
|
|
2024
Q3 | $1.98M | Buy |
17,186
+14,956
| +671% | +$2.05M | 0.01% | 673 |
|
|
2024
Q2 | $307K | Buy |
+2,230
| New | +$306K | ﹤0.01% | 1180 |
|
|
2024
Q1 | – | Sell |
-27,921
| Closed | -$3.68M | – | 1657 |
|
|
2023
Q4 | $3.68M | Sell |
27,921
-42,148
| -60% | -$4.85M | 0.02% | 512 |
|
|
2023
Q3 | $7.88M | Sell |
70,069
-92,200
| -57% | -$9.71M | 0.04% | 287 |
|
|
2023
Q2 | $15.3M | Sell |
162,269
-78,947
| -33% | -$7.71M | 0.08% | 194 |
|
|
2023
Q1 | $24.4M | Buy |
241,216
+64,612
| +37% | +$6.72M | 0.13% | 132 |
|
|
2022
Q4 | $21.1M | Sell |
176,604
-20,704
| -10% | -$2.43M | 0.12% | 134 |
|
|
2022
Q3 | $21M | Sell |
197,308
-17,389
| -8% | -$1.76M | 0.14% | 117 |
|
|
2022
Q2 | $20.9M | Buy |
214,697
+5,098
| +2% | +$471K | 0.13% | 125 |
|
|
2022
Q1 | $19.6M | Buy |
209,599
+157,512
| +302% | +$13.3M | 0.1% | 157 |
|
|
2021
Q4 | $4.44M | Buy |
+52,087
| New | +$4.79M | 0.02% | 356 |
|
|
2021
Q2 | – | Sell |
-4,586
| Closed | -$446K | – | 1057 |
|
|
2021
Q1 | $446K | Buy |
+4,586
| New | +$481K | ﹤0.01% | 806 |
|
|
2020
Q4 | – | Sell |
-10,499
| Closed | -$1.01M | – | 996 |
|
|
2020
Q3 | $1.01M | Buy |
+10,499
| New | +$1.21M | 0.01% | 621 |
|
|
2018
Q4 | – | Sell |
-2,975
| Closed | -$366K | – | 1012 |
|
|
2018
Q3 | $366K | Buy |
+2,975
| New | +$338K | ﹤0.01% | 755 |
|
|
2015
Q2 | – | Sell |
-35,500
| Closed | -$1.41M | – | 647 |
|
|
2015
Q1 | $1.41M | Sell |
35,500
-10,400
| -23% | -$372K | 0.01% | 270 |
|
|
2014
Q4 | $1.02M | Buy |
+45,900
| New | +$870K | 0.01% | 304 |
|
|
2014
Q1 | – | Sell |
-36,700
| Closed | -$364K | – | 743 |
|
|
2013
Q4 | $364K | Sell |
36,700
-55,600
| -60% | -$543K | ﹤0.01% | 558 |
|
|
2013
Q3 | $1.07M | Buy |
92,300
+67,300
| +269% | +$925K | 0.01% | 263 |
|
|
2013
Q2 | $353K | Buy |
+25,000
| New | +$307K | ﹤0.01% | 407 |
|
Other funds holding NBIX
Connor, Clark & Lunn Investment Management (CC&L)'s NBIX Position: Q2 2026 in Review
Connor, Clark & Lunn Investment Management (CC&L) sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 153,755 shares — an estimated $20.3M sold.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in NBIX in Q2 2013 and held it in 25 quarters. The position peaked at $39.5M in Q3 2025. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
- Connor, Clark & Lunn Investment Management (CC&L) sold 153,755 Neurocrine Biosciences shares in Q2 2026, an estimated $20.3M.
- Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 25 quarters.
- Connor, Clark & Lunn Investment Management (CC&L)'s Neurocrine Biosciences position peaked at $39.5M in Q3 2025.
- 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.